|
MSC source/type | Type of trial | Route of administration | Condition | Outcome | Reference |
|
Adipose/allogeneic | Phase 3 randomized, double-blind controlled trial | Intralesional injection | Perianal fistulas in CD | (i) Significant clinical remission (ii) Improved PDAI | [112] |
|
Bone marrow/allogeneic | Efficacy and safety study | Intravenous injection | UC | (i) Powerful immunomodulatory effects (ii) Reduced activity of autoimmune inflammation and stimulated reparative process in the intestinal mucosa, hence increasing the duration of remission, reducing the risk of recurrence of disease, and reducing the frequency of hospitalizations | [120] |
|
Bone marrow/allogeneic | Double-blind, placebocontrolled study | Intralesional injection | Perianal fistulas in CD | (i) Promoted healing of perianal fistulas (ii) Improved PDAI | [111] |
|
Umbilical cord | Non-randomized safety and therapeutic efficacy study | Intravenous infusion | Moderate to severe UC | (i) 30/36 patients treated with MSC showed good response (ii) Diffuse and deep ulcer formation and severe inflammatory mucosa were improved markedly (iii) -During the follow-up, the median Mayo score and histology score were decreased while IBDQ scores significantly improved | [121] |
|
Bone marrow/allogeneic | Phase 2, open-label, multicenter study | Intravenous infusions | Luminal CD | (i) Reduced CDAI and CDEIS scores (ii) Significant clinical remission | [108] |
|
Adipose/autologous | Long-term sustained response assessment | Submucosal fistula injection | Fistulas in CD | (i) High proportion of complete fistula closure (ii) Sustained efficacy and safety | [102] |
|
Adipose/autologous | Prospective phase I clinical trial | Fistula inoculation | Fistula in CD | (i) 6/8 fistulas completely healed. The other 2 with incomplete closure of the external opening | [114] |
|
Bone marrow/autologous | Phase I safety and feasibility study | Intravenous injection | Refractory CD | (i) Significantly reduced CDAI and CDEIS scores (ii) While 3/10 showed clinical response, another 3/10 required surgery due to disease worsening | [105] |
|
Adipose/allogeneic | Multicenter phase I/IIa clinical trial | Intralesionally injection | Perianal fistula in CD | (i) 56.3% of the patients achieved complete closure of the treated fistula (ii) MRI score of severity showed marked reduction at week 24 | [113] |
|
Adipose/allogeneic | Phase I-IIa clinical trial | Intralesional injection | Crohn’s-related rectovaginal fistula | 60% of patients achieved a complete healing | [115] |
|